SMMT
Summit TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
SMMT vs peer average
15/100
SMMT vs. peer average (F vs. C)
Grade spread
A 2 · B 2 · C 6 · F 1
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
MRK is the first available peer comparator.
Direct NSCLC immuno-oncology comparator because Summit's HARMONi-3 is designed against pembrolizumab plus chemotherapy, while Summit's 10-K also identifies Merck's sacituzumab tirumotecan among Phase III competitive candidates in first-line NSCLC [#10-K-2026-02-23].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SMMT
Summit Therapeutics
MRK
Merck
Grade
F
B
Momentum
11
62
Value
41
65
Sentiment
58
56
Setup Bias
Net Bullish
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs MRK
SMMT / MRK
Grade Position
Below peers
SMMT vs. peer average (F vs. C)
15/100
Momentum
11
MRKValue
41
MRKSentiment
58
SMMTRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SMMT
MRK is the first peer returned for this comparison set.